Figure 3.

Liponucleotide PEP improves lung function at 6 d.p.i. Effect of treating mice infected with H1N1 influenza A/WSN/33 (10,000 pfu/mouse) with sterile 0.9% saline (50 μl/mouse i.p.), 100 μg/mouse CDP-CHO (in 50 μl sterile 0.9% saline i.p.), or 100 μg/mouse CDP-CHO + 10 μg/mouse CDP-DAG (in 50 μl sterile 0.9% saline i.p.) daily from 1 to 5 d.p.i. on (A) R_BASAL (cm H₂O.s/ml; n ≥ 6/group), (B) C_ST (ml/cm H₂O × 10; n ≥ 6/group), (C) AFC₃₀ (percentage; n ≥ 5/group), and (D) BAL fluid σ_min achieved over 10 minutes (σ_min; mN/m; n = 2 samples/group and n = 3 mice/sample; flu + CDP-CHO + CDP-DAG group not done). All data were analyzed by ANOVA with a Tukey-Kramer multiple comparison post hoc test and are presented as mean ± SEM. *P < 0.05, **P < 0.005, and ^#P < 0.001 versus mock-inoculated mice. ^†P < 0.05 and ^§P < 0.001 versus saline-treated, IAV-infected mice. ^¶P < 0.001 versus CDP-CHO-treated, IAV-infected mice. σ_min = minimal stable surface tension; AFC₃₀ = alveolar fluid clearance rate; C_ST = static lung compliance; R_BASAL = basal airway resistance.